NPPA Fixes Retail Price Of 29 Formulations; Details

Published On 2020-11-06 11:15 GMT   |   Update On 2023-10-19 10:53 GMT
Advertisement

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 29 formulations.

These include some popular drug brands and combination formulations like Metformin Hydrochloride (SR), Gliclazide (ER) and Pioglitazone Hydrochloride Tablet; Clotrimazole and Lignocaine Hydrochloride Ear Drops; Atorvastatin plus Clopidogrel plus Aspirin Capsule (Atocor Gold 20); the combination of Vildagliptin and Metformin Hydrochloride (SR) Tablet and so on to treat various ailments.

Prominent drugmakers like Akum Drugs, Cipla, Indoco Remedies, Cadila Pharma, and others are involved in manufacturing the formulations mentioned in the list.

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl.

No.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1.

Moxifloxacin Hydrochloride + Dexamethasone Phosphate Eye Drop

Each ml contains:

Moxifloxacin Hydrochloride IP Eq. to Moxifloxacin 0.5% w/v, Dexamethasone Sodium Phosphate Eq. to Dexamethasone Phosphate 0.1% w/v,

1 ML

M/s Skymap Healthcare Pvt. Ltd./ M/s Albert David Ltd

19.02

2.

Ciprofloxacin + Dexamethasone Sodium Phosphate Eye

Drops

Composition:

Ciprofloxacin Hydrochloride IP Eq. to Ciprofloxacin 0.3% w/v, Dexamethasone IP 0.1% w/v

1 ML

M/s Skymap Healthcare Pvt. Ltd./M/s Albert David Ltd

1.35

3.

Ofloxacin + Dexamethasone Phosphate Eye/Ear Drops

Composition:

Ofloxacin IP 0.3% w/v, Dexamethasone Sodium Phosphate IP 0.1% w/v

1 ML

M/s Skymap Healthcare Pvt. Ltd./ M/s Albert David Ltd

3.77

4.

Ciprofloxacin + Dexamethasone Sodium Phosphate Eye Drops

Each ml contains:

Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 0.3% w/v, Dexamethasone Sodium Phosphate IP eq. to Dexamethasone Phosphate 0.1% w/v

1 ML

M/s Axa Parenterals Ltd. / M/s Sun Pharmaceuticals Industries Limited

1.35

5.

Telmisartan + Cilnidipine + Metoprolol Tablet (Telmiprime MC 25)

Each uncoated bilayered tablet contains:

Telmisartan IP 40mg Cilnidipine IP 10mg

Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartarate 25 mg (as Extended Release form)

1 Tablet

M/s Swiss Garnier Genexia Sciences Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

10.16

6.

Telmisartan + Cilnidipine + Metoprolol Tablet (Telmiprime MC 50)

Each uncoated bilayered tablet contains:

Telmisartan IP 40mg Cilnidipine IP 10mg

Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartarate 50 mg (as Extended Release form)

1 Tablet

M/s Swiss Garnier Genexia Sciences Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

12.41

7.

Metformin Hydrochloride (SR) + Gliclazide (ER) + Pioglitazone

Hydrochloride Tablet

Each Film Coated Bilayered Tablet Contain:

Metformin Hydrochloride IP 500mg (as Sustained Release Form) Gliclazide IP 30mg (as Extended

1 Tablet

M/s Swiss Garnier Genexia Sciences Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

6.15


(Prizide MP 30)

Release Form)

Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg.

8.

Metformin Hydrochloride (SR) + Gliclazide (ER) + Pioglitazone Hydrochloride Tablet (Prizide MP 60)

Each Film Coated Bilayered Tablet Contain:

Metformin Hydrochloride IP 500mg (as Sustained Release Form) Gliclazide IP 60mg (as Extended Release Form)

Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg.

1 Tablet

M/s Swiss Garnier Genexia Sciences Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

8.69

9.

Clotrimazole + Lignocaine Hydrochloride Ear Drops

Composition: Clotrimazole IP 1.0% w/v

Lignocaine Hydrochloride IP 2.0% w/v

1 ML

M/s Skymap Healthcare Pvt. Ltd.

5.93

10.

Moxifloxacin Hydrochloride + Dexamethasone Phosphate Eye Drops

Each ml contains:

Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 0.5% w/v Dexamethasone Sodium Phosphate IP eq. to Dexamethasone

Phosphate 0.1% w/v

1 ML

M/s Skymap Healthcare Pvt. Ltd.

19.02

11.

Atorvastatin + Clopidogrel + Aspirin Capsule (Atocor Gold 20)

Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As film coated tablet form),

Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet form),

Aspirin IP 75mg (As enteric coated Tablet form)

1

Capsule

M/s Akums Drugs & Pharmaceuticals Ltd. / Dr. Reddy's Laboratories Ltd.

5.50

12.

Rosuvastatin + Aspirin

+ Clopidogrel Capsule

Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Aspirin IP 75mg (as enteric coated pellets)

Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)

1

Capsule

M/s Synokem Pharmaceuticals ltd. / M/s Cadila Pharmaceuticals Limited

18.48

13.

Paracetamol + Caffeine Tablet

Each film coated tablet contains: Paracetamol IP 650mg

Caffeine Anhydrous IP 50mg

1 Tablet

M/s Acme Generics LLP / M/s Cipla Limited

2.74

14.

Azelnidipine + Telmisartan Tablet

Each film coated bi-layered tablet contains:

Azelnidipine IP 8mg Telmisartan IP 80mg

1 Tablet

M/s Synokem Pharmaceuticals Limited /

M/s Glenmark Pharmaceuticals Ltd.

16.16

15.

Azelnidipine + Telmisartan Tablet

Each film coated bi-layered tablet contains:

Azelnidipine IP 8mg Telmisartan IP 40mg

1 Tablet

M/s Synokem Pharmaceuticals Limited / M/s Glenmark Pharmaceuticals Ltd.

12.93

16.

Calcium + Vitamin D3 + Methylcobalamin + L- Methylfolate Calcium + Pyridoxal – 5- Phosphate Tablet

Each Film coated tablet contains: Calcium Carbonate IP 1250mg eq. to Elemental Calcium 500mg, Vitamin D3 IP 2000IU Mecobalamin IP (Methylcobalamin) 1500mcg,

L-Methylfolate Calcium 1mg, Pyridoxal – 5- Phosphate 20mg

1 Tablet

M/s Akums Drugs & Pharmaceuticals Limited / M/s Cipla Limited

17.78

17.

Azelnidipine + Telmisartan Tablet

Each film coated bi-layered tablet contains:

1 Tablet

M/s Synokem Pharmaceuticals Limited /

12.93

Azelnidipine IP 8mg Telmisartan IP 40mg

M/s Emcure Pharmaceuticals Ltd.

18.

Azelnidipine + Telmisartan Tablet

Each film coated bi-layered tablet contains:

Azelnidipine IP 8mg Telmisartan IP 80mg

1 Tablet

M/s Synokem Pharmaceuticals Limited / M/s Emcure

Pharmaceuticals Ltd.

14.40

19.

Flunarizine + Domperidone Tablet

Each uncoated tablet contains: Flunarizine Dihydrochloride BP eq. to Flunarizine 5mg, Domperidone IP 10mg

1 Tablet

M/s Windlas Biotech Pvt. Ltd./M/s Mankind Pharma Limited

4.68

20.

Budesonide + Glycopyrronium Bromide + Formoterol Fumarate Powder for Inhalation

Each Capsule contains: Budesonide IP 400 mcg, Glycopyrronium (As Glycopyrrolate IP) 25mcg,

Formoterol Fumarate Dihydrate IP 12 mcg

1

Capsule

M/s Cipla Limited

13.63

21.

Alogliptin + Metformin Hydrochloride Tablet

Each film coated tablet contains: Alogliptin Benzoate 17mg eq. to Alogliptin 12.5 mg ,

Metformin Hydrochloride IP 500MG

1 Tablet

M/s Indoco Remedies Limited

7.82

22.

Alogliptin + Metformin Hydrochloride Tablet

Each film coated tablet contains: Alogliptin Benzoate 17mg eq. to Alogliptin 12.5 mg,

Metformin Hydrochloride IP 1000 mg

1 Tablet

M/s Indoco Remedies Limited

9.49

23.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50 mg,

Metformin Hydrochloride 500 mg (as sustained release form)

1 Tablet

M/s Mascot Health Series Pvt. Ltd./M/s Emcure Pharmaceutical Limited

6.58

24.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50mg,

Metformin Hydrochloride IP 500mg (As sustained release form)

1 Tablet

M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd.

6.58

25.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50mg,

Metformin Hydrochloride IP 500mg (As sustained release form)

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Limited

6.58

26.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50 mg,

Metformin Hydrochloride 1000 mg (as sustained release form)

1 Tablet

M/s Mascot Health Series Pvt. Ltd./M/s Emcure Pharmaceutical Limited

7.07

27.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50mg, Metformin Hydrochloride IP

1000mg (As sustained release form)

1 Tablet

M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd.

7.07

28.

Vildagliptin + Metformin Hydrochloride (SR) Tablet

Each uncoated bilayered tablet contains:

Vildagliptin 50mg,

Metformin Hydrochloride IP 1000mg (As sustained release form)

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Limited

7.07

29.

Recombinant Rabies G Protein Vaccine 2ml

Each vial of 0.5ml contains: rRabies G Protein 50.00 µg

1 Vial

M/s Cadila Pharmaceuticals Limited

681.44

Sl.

No.

Name of the Formulation / Brand

Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Glass vial

Disodium Hydrogen Phosphate Anhydrous IP 0.87mg Monobasic Sodium Phosphate Monohydrate BP 0.88mg Sodium Chloride IP 8.76mg

Tergitol NP9 0.1 µl

The NPPA notification further added-

(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.
To access the official notice, click on the link below-
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News